Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR31 Adjuvant Durvalumab in Resected NSCLC
2024-517856-36-00Phase 3Completed
- Sponsor
- NVALT-studies Stichting, Intergroupe Francophone De Cancerologie Thoracique, Fundacion GECP, Queen's University, Clinipace Global Limited
- Start
- Nov 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab with Placebo (2 arms). Primary endpoint: Disease-free survival (DFS) in PD-L1 TC ≥ 25% and EGFR-/ALK- population. Started Nov 2024; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-517856-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517856-36-00.